Employers are constantly challenged with the arduous task of managing their specialty drug spend. With pharmacy costs rising, it's time for benefits purchasers to implement specialty drug management programs focusing on member/employee well-being to improve health outcomes. Employers have seen significant reductions in specialty pharmacy spending by moving away from traditional PBM models, carving out specialty drugs, and using data to identify medications that impact the patient.
Alternative Funding vendors promise employers and employees “free drugs” by accessing Patient Assistance Programs. Recently, pharmaceutical manufacturers have begun denying these vendors access to Patient Assistance funds, and lawsuits have been filed against some of these vendors. Listen to the specialty drugs experts from VIVIO and the ERISA law experts from Frier Levitt.
To the casual observer, the optimistic discussion swirling around Humira biosimilars seems as if these competitor drugs will provide some relief to the country’s specialty drug problem. Unfortunately, the opposite is true; and our best opportunity in a generation to break the PBM stranglehold will be wasted. VIVIO hosted an important webinar to answer critical questions facing employers and others responsible for managing specialty drugs. Topics included:
©2023 VIVIO Health Inc. All rights reserved.
